# A Study of M701 (EpCAM and CD3) in Malignant Ascites

> **NCT04501744** · PHASE1 · COMPLETED · sponsor: **Wuhan YZY Biopharma Co., Ltd.** · enrollment: 35 (actual)

## Conditions studied

- Malignant Ascites
- Cancer

## Interventions

- **DRUG:** Cohort 1 of M701
- **DRUG:** Cohort 2 of M701
- **DRUG:** Cohort 3 of M701
- **DRUG:** Cohort 4 of M701
- **DRUG:** Cohort 5 of M701
- **DRUG:** Cohort 6 of M701
- **DRUG:** Cohort 7 of M701

## Key facts

- **NCT ID:** NCT04501744
- **Lead sponsor:** Wuhan YZY Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-30
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-09-30
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501744, "A Study of M701 (EpCAM and CD3) in Malignant Ascites". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04501744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*